Who Supplies Serum to India from SDNF

To import finished pharmaceutical formulations containing serum into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the manufacturing site and the product be registered. The registration process involves obtaining a Registration Certificate for the manufacturing premises and an Import License for the specific drug. The application must be submitted to the Drugs Controller General (I) at CDSCO. The fee for registering the manufacturing unit is USD 1,500, and for registering each drug, it is USD 1,000. The validity of both the Registration Certificate and Import License is three years from the date of issue.

Imported pharmaceutical formulations containing serum must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, is essential to demonstrate the product's shelf-life in India's climate. Port inspections by customs drug inspectors are conducted to ensure adherence to these standards.

In April 2025, the Indian government introduced new regulations requiring import registration and licenses for all imported medicines, including finished pharmaceutical formulations containing serum. This measure aims to prevent the sale of unapproved or illegal medicines in the Indian market. The Central Drugs Standard Control Organization (CDSCO) emphasized that both the manufacturing site and the product must be registered to ensure quality, safety, and efficacy.

India imports finished pharmaceutical formulations containing serum to access patented or branded products, specialized dosage forms, and formulations not produced domestically. The domestic pharmaceutical industry may lack the capacity or technology to manufacture certain serum-based formulations, leading to reliance on imports. The Indian market for serum formulations is substantial, with a total export value of $27.1 million across 341 exporters to 122 countries.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations containing serum under HS Code 30029090 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 10.30%. There are no additional duties or exemptions specified for Sdnf origin.

India sources finished pharmaceutical formulations containing serum from Sdnf due to competitive advantages such as patented formulations, specialized dosage forms, and high-quality products. Sdnf's pharmaceutical industry offers formulations that may not be available from other suppliers like China, Germany, or the US. While other countries also supply serum formulations, Sdnf's unique offerings and quality standards make it a preferred source for certain products.

India imports finished pharmaceutical formulations containing serum from Sdnf to access unique formulations, patented products, and specialized dosage forms not available domestically. Sdnf's pharmaceutical industry offers high-quality products that meet international standards, making them attractive to Indian importers seeking to diversify their product offerings.

Compared to other origins like China, the European Union, and the United States, Sdnf offers competitive pricing and high-quality formulations. While other countries may have larger production capacities, Sdnf's focus on specialized and patented formulations provides a unique advantage. Regulatory compliance and reliability are also key factors that make Sdnf a preferred source for certain serum formulations.

Potential risks for Indian importers sourcing finished pharmaceutical formulations containing serum from Sdnf include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, monitoring currency exchange rates, staying updated on regulatory changes, and establishing contingency plans for logistics.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Clarify MOQs to ensure they align with demand forecasts.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers to ensure compliance with quality and regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the manufacturing premises and the drug with CDSCO.
3. 3Import License: Apply for an Import License from CDSCO.
4. 4No Objection Certificate (NOC): If required, obtain an NOC from the Ministry of Health and Family Welfare.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30029090 to confirm classification and applicable duties.

1. 1Certificate of Analysis (CoA): Confirming product quality and compliance.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating regulatory approval in Sdnf.
3. 3Good Manufacturing Practice (GMP) Certificate: Demonstrating adherence to manufacturing standards.
4. 4Drug Master File (DMF): Providing detailed information on the drug's composition and manufacturing process.
5. 5Stability Data: